There was no appreciable decrease in audio quality from the increase in digital power levels. This finding allowed the broadcast industry to become comfortable with the benefits of increasing digital power levels for the HD Radio system and allowed the industry to seek FCC authorization for an overall increase in digital power levels. Various broadcasters supported iBiquity’s request to allow broadcasters to increase the power level of their digital radio broadcasts. On January 29, 2010, the FCC issued an order authorizing FM radio stations to increase their digital power levels based on the test results conducted pursuant to the MIPS grant. iBiquity also distributed results to regulators in other countries considering HD Radio adoption and to the International Telecommunication Union. The information about high-power FM broadcasts helped to encourage the Mexican government to adopt HD Radio technology as the digital radio standard in Mexico. The FCC authorization of increased power resulted in several dozen stations around the country increasing the power levels of their digital broadcasts and improving the quality of their digital signals.

The project has shown that the polymer-drug conjugate inhibited tumor growth significantly in tumor-bearing animal models. Rexahn is conducting further preclinical development to move this project toward the human trials.

The project results supported the original hypothesis that CTA1 DNA immunization can be used in rhesus macaques and supported its further development as a means by which immune responses to DNA vaccines could be augmented. The project enabled Profectus to receive a $6.25 million grant from the National Institute of Allergy and Infectious Diseases.

The company has raised $10.29 million in venture funding over two rounds, as well as total of $34.19 million in total funding, including grants, according to Crunchbase.

Profectus vaccines are based on the company’s proprietary VesiculoVax™ and DNA vaccine delivery platforms. The DNA vaccine platform is being harnessed for therapeutic vaccines for immune-mediated disorders, including food allergies and autoimmune disorders. These DNA vaccines rely on the actions of proprietary tolerogenic adjuvants. Used alone, the first-in-class VesiculoVax™-vectored vaccines lead to rapid expansion of B cells to provide protection against emerging infectious diseases of public health and biodefense importance, such as Ebola, Marburg, Chikungunya, Zika, the equine encephalitis viruses, and respiratory syncytial virus. When used as a boost after priming the immune system with best-in-class DNA vaccines, VesiculoVax™-vectored vaccines lead to the expansion of primed T cells into effector cells that are uniquely suited to attacking virally infected cells and cancers. Current programs using this Prime/Boost System of Vaccines (PBS Vax™) strategy include hepatitis B virus (HBV), human papilloma virus (HPV), herpes simplex virus type 2 (HSV-2), universal Influenza and human immunodeficiency virus (HIV).

The prime/boost vaccines also incorporate established and novel, proprietary adjuvants, including IL-12, CTA1 and RALDH2, which is the only known adjuvant that can elicit robust mucosal immunity from systemic immunizations. Partners and collaborators include the Galveston National Laboratory at UTMB, Yale University, the Institute of Human Virology, the Center for HIV/AIDS Vaccine Immunology, the National Cancer Institute, the NIH Division of AIDS, the Bill and Melinda Gates Foundation, the International AIDS Vaccine Initiative, the HIV Vaccines Trials Network, and the AIDS Clinical Trials Group. Profectus has been funded by Cross Atlantic Capital Partners (“XACP”) of Radnor, 3/3 Pennsylvania. XACP’s primary investor is the Pennsylvania Public School Employees’ Retirement System (PSERS).